Skip to main content
JAMA internal medicine
Faster Drug Approvals Are Not Always Better and Can Be Worse.
Improving Manufacturer Reporting of Adverse Events to the US Food and Drug Administration.
Would a Breakthrough Therapy by Any Other Name Be as Promising?
Appropriate Use Criteria Require Data.
An Intervention to Reduce Use of Low-Value Imaging Tests.
Use of Prostate-Specific Antigen Testing Is in the Eye of the Beholder.
Firearm Injuries and Gun Violence: Call for Papers.
Continuing Use of Prophylactic Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease Despite Evidence of No Benefit: Déjà Vu All Over Again.
Low-Density Lipoprotein Cholesterol Levels and Statin Treatment-A Moving Target?
